Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | voltage gated potassium channel | 0.0032 | 0.0563 | 0.0563 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0104 | 0.451 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.0563 | 0.1145 |
Loa Loa (eye worm) | voltage and ligand gated potassium channel | 0.0112 | 0.4913 | 1 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0112 | 0.4913 | 0.4913 |
Brugia malayi | Voltage-gated potassium channel, HERG (KCNH2)-related. C. elegans unc-103 ortholog | 0.0112 | 0.4913 | 1 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0032 | 0.0563 | 0.0563 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0122 | 0.5476 | 0.5476 |
Echinococcus granulosus | potassium voltage gated channel subfamily H | 0.0032 | 0.0563 | 0.0563 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0032 | 0.0563 | 0.0563 |
Echinococcus granulosus | voltage gated potassium channel | 0.0032 | 0.0563 | 0.0563 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0032 | 0.0563 | 0.0563 |
Trichomonas vaginalis | voltage and ligand gated potassium channel, putative | 0.0104 | 0.451 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0097 | 0.4104 | 0.8354 |
Echinococcus multilocularis | potassium voltage gated channel subfamily H | 0.0112 | 0.4913 | 0.4913 |
Brugia malayi | Voltage-gated potassium channel, EAG (KCNH1)-related. C. elegans egl-2 ortholog | 0.0032 | 0.0563 | 0.1145 |
Schistosoma mansoni | voltage-gated potassium channel | 0.0122 | 0.5476 | 0.5476 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 6.5733 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 18.3564 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PubChem BioAssay. Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.